eLife Review Time

eLife is unusual because the citation history still matters even though the journal no longer carries a current JIF.

The last listed JIF was down from 8.7 in 2021 to 7.6 in 2022, and then the journal was not listed from 2023 onward after leaving JCR. That means the old citation profile still says something about visibility, but the submission decision now turns much more on whether the reviewed-preprint model fits your paper and career context.

Under the traditional model (pre-2023), eLife accepted about 15% of submissions after peer review. Under the new model, eLife doesn't reject papers after review. Instead:

1. Papers undergo initial assessment by a senior editor and reviewing editor
2. Papers deemed suitable are sent for full peer review
3. Reviews are published alongside the paper as a "reviewed preprint"
4. Each paper receives an assessment categorizing its significance and strength of evidence
5. Authors can revise based on reviews. Revised versions are published with the original reviews

eLife doesn't review everything. The initial assessment filters papers that are outside scope, have fundamental methodological problems, or aren't suitable for the eLife audience. This assessment happens in 1-2 weeks and serves a similar function to desk rejection at traditional journals, even though the later workflow is very different.

eLife uses a distinctive consultation process where reviewers discuss their assessments before the editorial assessment is finalized. This produces a more coherent, consolidated set of feedback than the independent reviewer reports at most journals. It also means reviewers can't contradict each other without resolving the disagreement.

Each reviewed preprint receives two ratings:

• Significance: Landmark, Fundamental, Important, Useful
• Strength of evidence: Exceptional, Compelling, Convincing, Solid, Incomplete, Inadequate

A paper rated "Landmark / Exceptional" is equivalent to an enthusiastic acceptance at a traditional journal. A paper rated "Useful / Incomplete" is equivalent to a rejection with revision suggestions.

The ratings become part of the permanent record alongside the paper.

Initial assessment decline (1-2 weeks): The editors didn't think the paper was suitable for eLife's review process. Not published as a reviewed preprint.

Fast review cycle (4-6 weeks): Reviewers respond quickly, consultation is brief. The paper and reviews are published promptly.

Slow review (8+ weeks): A reviewer is late or the consultation process reveals disagreements that need resolution. Not unusual.

Revision cycle (variable): Authors have no deadline to revise. Some revise in weeks, some take months. The original reviewed preprint remains published.

eLife's timeline makes sense only if you understand the new model as a publication-with-reviews workflow rather than a classic accept-reject workflow. The next useful questions are usually about fit, process, and whether the public-review model is strategically right for the paper:

• eLife submission process
• eLife impact factor
• eLife pre-submission checklist

The main mistake is reading eLife's 4-8 week review cycle as if it were equivalent to a standard first-decision clock at another journal. It is not. At eLife, that window ends with a reviewed preprint and public assessment, not with the private yes-or-no decision most authors are used to.

That changes the strategic question for the author. The right question is not only "how fast is eLife?" It is "am I comfortable having the paper's first substantial critique become part of the public record on that timeline?" For some papers that is a feature. For others, it changes the journal choice entirely.

In our pre-submission review work with manuscripts considering eLife, three patterns generate the most consistent initial-assessment declines.

Authors treating the model as easier than a traditional journal. We see this pattern in roughly 35% of eLife manuscripts we review. The paper is good, but the submission logic assumes that transparent review will rescue a package that is still one experiment or one framing pass short of public exposure.

Claims that would attract a weak public evidence rating. eLife's current model makes the strength-of-evidence assessment part of the permanent record. Editors specifically screen whether the paper is ready for public review rather than private negotiation, and in our experience roughly 30% of eLife manuscripts we audit would face a weaker public assessment than the authors expect because the causal claim outruns the data package.

Field fit that is good science but weak eLife audience fit. The eLife model works best when the paper belongs in a life-science conversation that can read reviewed preprints on their own merits. Our review of eLife submissions repeatedly finds that roughly 20% of manuscripts are better served by a more conventional journal because the strongest audience is still evaluating papers through private accept-reject outcomes and journal-level shorthand.

Published timelines are medians that can mask real variation. Desk rejections (often 1-3 weeks) skew the median down, making the number shorter than what reviewed papers actually experience. Seasonal effects (December submissions sit longer, September backlogs) and field-specific reviewer availability also affect your specific wait time. The timeline does not include acceptance-to-publication time.

An eLife desk-rejection risk and review delay check identifies desk-reject risk before you submit.